Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cep-32496. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 8/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cep-32496 SCHEMBL1015932 | 1.00 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL29351427 | 1.00 | BRAF (1.00) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL29726019 | 0.99 | BRAF (0.98) | BRAFRAF1RIPK2JAK2ABL1 | |
| Cep-32496 SCHEMBL18155156 | 0.99 | BRAF (0.98) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL16156073 | 0.96 | BRAF (0.93) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL17053430 | 0.96 | BRAF (0.92) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1011649 | 0.95 | BRAF (0.91) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL17679303 | 0.94 | BRAF (0.90) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1013252 | 0.94 | BRAF (0.90) | BRAFRAF1RIPK2JAK2ABL1 | |
| SCHEMBL1011900 | 0.94 | BRAF (0.90) | BRAFRAF1RIPK2JAK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240310266-A1 | BIOMARKERS FOR CANCER AND METHODS OF USE THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-09-19 | — | — | US | disclosed |
| EP-3284481-B1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, AGENT FOR INHIBITING PROLIFERATION OF SAID CELLS AND PHARMACEUTICAL COMPOSITION FOR TREATING PATIENT SUFFERING FROM EFFECTS OF ABNORMAL PROLIFERATION OF SAID CELLS | NITTO DENKO CORP (JP) | 2024-05-15 | — | — | EP | disclosed |
| CN-117321418-A | Cancer biomarkers and methods of use thereof | 诺华股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4106761-A1 | TREATMENT OF CORNEAL VASCULARISATION | Vestlandets Innovasjonsselskap AS (NO) | 2022-12-28 | — | — | EP | disclosed |
| CN-110403941-B | Broad-spectrum antiviral drug or composition | 中国农业大学 | 2022-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240310266-A1 | BIOMARKERS FOR CANCER AND METHODS OF USE THEREOF | PDCD1, PDCD1LG2, CD274 | BRAF 4/4885EGFR 70/4885RET 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.